Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates
Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences,...
NYSE: TAK
Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period...
Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...
Takeda’s Entyvio Receives Historic Patent Term Adjustment in China, a First for the Country
On August 16, a significant milestone was reached as the China National Intellectual Property Administration...
Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach
Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly...
Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort
Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...
Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials
Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...
Takeda Strikes Deal with AC Immune for Global Rights to Alzheimer’s Immunotherapies
Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA...
HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...
Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline
Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this...
US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment
The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...